Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Mix and Match del vaccino COVID-19 per la sicurezza e l'immunogenicità (MOSAIC)

8 novembre 2026 aggiornato da: Canadian Immunization Research Network

Immunogenicità ed eventi avversi dopo l'immunizzazione (AEFI) con programmi alternativi di vaccini COVID-19 in Canada: è "Mix and Match" della seconda dose (MOSAIC-1; CT24a) e della terza dose (MOSAIC-2; CT24b) sicuro e immunogenico ?

The main goals of this study are to assess the immune response and safety of two different vaccines for first, second, third and fourth doses as well as for differing intervals between the first and second dose of two-dose vaccines.

Panoramica dello studio

Descrizione dettagliata

For dose 1 and 2, the currently available mRNA vaccines (Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273) are two dose vaccines which were studied in schedules of either 0 and 21 days or 0 and 28 days, respectively. The ChAdOx1 nCOV-19 (Astra-Zeneca) adenovirus-vectored vaccine is authorized to be given in two doses one month to 12 weeks apart. We will compare the interval 0, 28 days to a 0, 112 days (16 weeks) schedule, and assess the immunogenicity of both heterogeneous and heterologous second doses using the Canadian schedule.

For dose 3, the currently available mRNA vaccines (Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273) and plant-based virus-like particle (Medicago Covifenz) are anticipated to be administered 6 months apart. We will assess the immunogenicity of both heterogeneous and heterologous third doses using the Canadian schedule.

For dose 4, the currently available mRNA vaccines (Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273) and plant-based virus-like particle (Medicago Covifenz) are anticipated to be administered 3 months apart. We will assess the immunogenicity of both heterogeneous and heterologous third doses using the Canadian schedule.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

669

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • British Columbia
      • Kamloops, British Columbia, Canada
        • Royal Inland Hospital
      • Penticton, British Columbia, Canada
        • Penticton Regional Hospital
      • Vancouver, British Columbia, Canada, V5Z 4H4
        • BC Children's Hospital Research Institute
    • Manitoba
      • Winnipeg, Manitoba, Canada
        • Children's Hospital Research Institute of Manitoba
    • Nova Scotia
      • Halifax, Nova Scotia, Canada
        • Canadian Center for Vaccinology
    • Ontario
      • Ottawa, Ontario, Canada
        • Ottawa Hospital Research Institute, University of Ottawa
    • Quebec
      • Montreal, Quebec, Canada, H9H 4Y6
        • McGill University Health Centre Vaccine Study Centre
      • Québec, Quebec, Canada
        • CHU de Québec, Université Laval

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 99 anni (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Participant is willing and able to give written informed consent to participate in the study
  2. Age 18 years of age or older in good health or with mild or moderate stable co-morbidities at the time of enrolment
  3. Able and willing to complete all the scheduled study procedures during the whole study follow-up period
  4. If female of child-bearing potential and heterosexually active, has practiced adequate contraception for 30 days prior to injection, has a negative pregnancy test on the day of injection, and has agreed to continue adequate contraception until 3 months after the final dose of study vaccine (Please refer to the definition section for a description of child-bearing potential and adequate contraception)
  5. MOSAIC-1 Vaccine-exposed subgroups: have received or are booked to receive the first dose of an authorized COVID-19 vaccine in the 55 days prior to Visit 1 (documentation of receipt required)
  6. MOSAIC -1 Vaccine naïve subgroups: have not received an authorized COVID-19 vaccine at any time
  7. MOSAIC-2 participants have received two doses of COVID-19 vaccines authorized in Canada ≥6 months prior to study vaccine administration (documentation of receipt required)
  8. MOSAIC-3 participants have received three doses of COVID-19 vaccines authorized in Canada ≥3 months prior to study vaccine administration (documentation of receipt required)

Exclusion Criteria:

  1. Inability or unwillingness of participant or legally acceptable representative to give written informed consent
  2. Any confirmed or suspected immunosuppressive or immunodeficient state; asplenia, or immunosuppressant medication within the past 6 months except short term oral steroids (≤14 days duration) or topical steroids
  3. Current diagnosis or treatment for cancer (except basal cell carcinoma of the skin)
  4. Administration of immunoglobulins and/or any blood products within 3 months preceding the first dose of study vaccine and for one month after the last dose of study vaccine
  5. Allergy to any study vaccine or any active substance in a study vaccine
  6. Bleeding disorder or history of significant bleeding following IM injections or venipuncture
  7. Continuous use of anticoagulants
  8. A history of anaphylaxis to a previous vaccine
  9. Pregnancy or intent to become pregnant during the study or within 3 months of the last dose of study vaccine
  10. MOSAIC-1: History of laboratory-confirmed COVID-19 disease prior to enrolment by participant report
  11. Administration of a live virus vaccine within 4 weeks prior to study vaccine receipt.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Group 1: Moderna, Moderna - 28 Days apart

Participants will be blinded and receive two doses (0.20 mg/mL each) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle 28 days apart.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

Altri nomi:
  • Spikevax
  • Vaccino COVID-19 Moderna

Second injection administered 28 days post first injection

Comparatore attivo: Group 2: Moderna, Moderna - 112 days apart

Participants will be blinded and receive two doses (0.20 mg/mL each) of mRNA-1273 SARS-CoV-2 vaccine at 0.20 mg/mL via intramuscular injection in the deltoid muscle 112 days apart.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

Altri nomi:
  • Spikevax
  • Vaccino COVID-19 Moderna

Second injection administered 112 days post first injection

Comparatore attivo: Group 3: Moderna, Pfizer/BioNTech - 28 days apart

Participants will be blinded and receive one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3mL) of BNT162b2 vaccine after 28 days.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

Altri nomi:
  • Spikevax
  • Vaccino COVID-19 Moderna

Second injection administered 28 days post first injection

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

Altri nomi:
  • Comirnaty
  • Vaccino Pfizer-BioNTech COVID-19
Comparatore attivo: Group 4: Moderna, Pfizer/BioNTech - 112 days apart

Participants will be blinded and receive one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3mL) of BNT162b2 vaccine after 112 days.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

Altri nomi:
  • Spikevax
  • Vaccino COVID-19 Moderna

Second injection administered 112 days post first injection

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

Altri nomi:
  • Comirnaty
  • Vaccino Pfizer-BioNTech COVID-19
Comparatore attivo: Group 5: Pfizer/BioNTech, Pfizer/BioNTech - 28 days apart

Participants will be blinded and receive two doses (0.3mL each) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle 28 days apart.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Second injection administered 28 days post first injection

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

Altri nomi:
  • Comirnaty
  • Vaccino Pfizer-BioNTech COVID-19
Comparatore attivo: Group 6: Pfizer/BioNTech, Pfizer/BioNTech - 112 days apart

Participants will be blinded and receive two doses (0.3mL each) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle 112 days apart.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Second injection administered 112 days post first injection

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

Altri nomi:
  • Comirnaty
  • Vaccino Pfizer-BioNTech COVID-19
Comparatore attivo: Group 7: Pfizer/BioNTech, Moderna - 28 days apart

Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 28 days.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

Altri nomi:
  • Spikevax
  • Vaccino COVID-19 Moderna

Second injection administered 28 days post first injection

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

Altri nomi:
  • Comirnaty
  • Vaccino Pfizer-BioNTech COVID-19
Comparatore attivo: Group 8: Pfizer/BioNTech, Moderna - 112 days apart

Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 112 days.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

Altri nomi:
  • Spikevax
  • Vaccino COVID-19 Moderna

Second injection administered 112 days post first injection

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

Altri nomi:
  • Comirnaty
  • Vaccino Pfizer-BioNTech COVID-19
Comparatore attivo: Group 9: Astra Zeneca, Moderna - 28 days apart

Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 28 days.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

Altri nomi:
  • Spikevax
  • Vaccino COVID-19 Moderna

Second injection administered 28 days post first injection

A colourless to slightly brown, clear to slightly opaque solution containing 5 x 1010 viral particles (not less than 2.5 x 108 infectious units).

Altri nomi:
  • Vaxzevria
  • Vaccino Astra Zeneca COVID-19
  • COVISHIELD Vaccino AstraZeneca COVID-19
Comparatore attivo: Group 10: Astra Zeneca, Moderna - 112 days apart

Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 112 days.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

Altri nomi:
  • Spikevax
  • Vaccino COVID-19 Moderna

Second injection administered 112 days post first injection

A colourless to slightly brown, clear to slightly opaque solution containing 5 x 1010 viral particles (not less than 2.5 x 108 infectious units).

Altri nomi:
  • Vaxzevria
  • Vaccino Astra Zeneca COVID-19
  • COVISHIELD Vaccino AstraZeneca COVID-19
Comparatore attivo: Group 11: Astra Zeneca, Pfizer/BioNTech - 28 days apart

Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3 mL) of BNT162b2 vaccine after 28 days.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Second injection administered 28 days post first injection

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

Altri nomi:
  • Comirnaty
  • Vaccino Pfizer-BioNTech COVID-19

A colourless to slightly brown, clear to slightly opaque solution containing 5 x 1010 viral particles (not less than 2.5 x 108 infectious units).

Altri nomi:
  • Vaxzevria
  • Vaccino Astra Zeneca COVID-19
  • COVISHIELD Vaccino AstraZeneca COVID-19
Comparatore attivo: Group 12: Astra Zeneca, Pfizer/BioNTech - 112 days apart

Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3 mL) of BNT162b2 vaccine after 112 days.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Second injection administered 112 days post first injection

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

Altri nomi:
  • Comirnaty
  • Vaccino Pfizer-BioNTech COVID-19

A colourless to slightly brown, clear to slightly opaque solution containing 5 x 1010 viral particles (not less than 2.5 x 108 infectious units).

Altri nomi:
  • Vaxzevria
  • Vaccino Astra Zeneca COVID-19
  • COVISHIELD Vaccino AstraZeneca COVID-19
Comparatore attivo: Group 1b

Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

Altri nomi:
  • Comirnaty
  • Vaccino Pfizer-BioNTech COVID-19
Comparatore attivo: Group 2b

Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

Altri nomi:
  • Spikevax
  • Vaccino COVID-19 Moderna
Comparatore attivo: Group 3b

Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

Altri nomi:
  • Spikevax
  • Vaccino COVID-19 Moderna
Comparatore attivo: Group 4b

Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

Altri nomi:
  • Comirnaty
  • Vaccino Pfizer-BioNTech COVID-19
Comparatore attivo: Group 5b

Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

Altri nomi:
  • Spikevax
  • Vaccino COVID-19 Moderna
Comparatore attivo: Group 6b

Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

Altri nomi:
  • Comirnaty
  • Vaccino Pfizer-BioNTech COVID-19
Comparatore attivo: Group 7b

Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

Altri nomi:
  • Comirnaty
  • Vaccino Pfizer-BioNTech COVID-19
Comparatore attivo: Group 8b

Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

Altri nomi:
  • Spikevax
  • Vaccino COVID-19 Moderna
Sperimentale: Group 9b

Participants will receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.

COVIFENZ is an emulsion for intramuscular injection. The 3.75 mcg antigen component of COVIFENZ is a suspension, which must be mixed 1:1 with the 0.25 mL AS03 adjuvant emulsion component prior to administration

Altri nomi:
  • Vaccino Medicago COVID-19
Comparatore attivo: Group 1c

Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

Altri nomi:
  • Comirnaty
  • Vaccino Pfizer-BioNTech COVID-19
Comparatore attivo: Group 2c

Participants will be blinded and receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.

COVIFENZ is an emulsion for intramuscular injection. The 3.75 mcg antigen component of COVIFENZ is a suspension, which must be mixed 1:1 with the 0.25 mL AS03 adjuvant emulsion component prior to administration

Altri nomi:
  • Vaccino Medicago COVID-19
Comparatore attivo: Group 3c

Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

Altri nomi:
  • Spikevax
  • Vaccino COVID-19 Moderna
Comparatore attivo: Group 4c

Participants will be blinded and receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.

COVIFENZ is an emulsion for intramuscular injection. The 3.75 mcg antigen component of COVIFENZ is a suspension, which must be mixed 1:1 with the 0.25 mL AS03 adjuvant emulsion component prior to administration

Altri nomi:
  • Vaccino Medicago COVID-19
Comparatore attivo: Group 5c

Participants will be blinded and receive either one dose (0.3mL) of BNT162b2 or one half dose (0.25mL) of mRNA-1273 via intramuscular injection in the deltoid muscle.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

Altri nomi:
  • Spikevax
  • Vaccino COVID-19 Moderna

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

Altri nomi:
  • Comirnaty
  • Vaccino Pfizer-BioNTech COVID-19
Comparatore attivo: Group 6c

Participants will be blinded and receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.

COVIFENZ is an emulsion for intramuscular injection. The 3.75 mcg antigen component of COVIFENZ is a suspension, which must be mixed 1:1 with the 0.25 mL AS03 adjuvant emulsion component prior to administration

Altri nomi:
  • Vaccino Medicago COVID-19
Sperimentale: Group 7c

Participants will receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.

COVIFENZ is an emulsion for intramuscular injection. The 3.75 mcg antigen component of COVIFENZ is a suspension, which must be mixed 1:1 with the 0.25 mL AS03 adjuvant emulsion component prior to administration

Altri nomi:
  • Vaccino Medicago COVID-19

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Antibody response to SARS-CoV-2 S protein after 2 doses
Lasso di tempo: Day 56

The co-primary outcome for the non-inferiority comparison of 0, 28-day schedules with heterologous second dose is the immune response to SARS-CoV-2 at day 56 (28 days after the second dose of vaccine) based on anti-spike antibody titers.

Day 56
Antibody response to SARS-CoV-2 S protein after 2 doses
Lasso di tempo: Day 140

The co-primary outcome for the non-inferiority comparison of schedules in which the timing of the second dose of vaccine is different (0, 28 days v 0, 112 days) is the immune response to SARS-CoV-2 at day 140 (28 days after the last dose in the 0, 112 day schedule) based on anti-spike antibody titers.

Day 140
Antibody response to SARS-CoV-2 S protein after 3 doses
Lasso di tempo: Day 28

To determine if a vaccination schedule with a heterologous third dose of a COVID-19 vaccine induces a non-inferior serum immune response to SARS-CoV-2, compared to a third dose/booster with a homologous vaccine.

Day 28
Antibody response to SARS-CoV-2 S protein after 4 doses
Lasso di tempo: Day 28

To determine if a vaccination schedule with a heterologous fourth dose of a COVID-19 vaccine induces a non-inferior serum immune response to SARS-CoV-2, compared to a third dose/booster with a homologous vaccine.

Day 28

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Durability of antibody response to SARS-CoV-2 S over 12 months after 2 doses
Lasso di tempo: Baseline and Days 28, 56, 112, 140, 365

Assess durability of immune responses in each study group over 12 months based on anti-spike antibody titers and pseudoneutralization assay.

Baseline and Days 28, 56, 112, 140, 365
Pseudoneutralization assay, T cell testing, Antibody dependent cellular cytotoxicity (ADCC), Antibody avidity, RNA seq after 2 doses
Lasso di tempo: Days 28, 56, 112, 140, 365

Characterization of the immune response to COVID-19 vaccines in schedules with 0, 28 days versus 0, 112 days dosing and heterologous schedules to day 365.

Days 28, 56, 112, 140, 365
Incidence of grade 3 solicited local and systemic adverse events, SAEs, AEFIs, MAAEs, AESIs in the 7 days following vaccine receipt after 2 doses
Lasso di tempo: From time of first study injection through Day 365.

Description of safety outcomes over 12 months post-vaccination including SAEs (serious adverse events), provincially reportable AEFIs (adverse events following immunization), MAAEs (medically attended adverse events), AESIs (adverse events of special interest).

From time of first study injection through Day 365.
Incidence of grade 3 solicited local and systemic adverse events, SAEs, AEFIs, MAAEs, AESIs in the 7 days following vaccine receipt after 3 doses
Lasso di tempo: From time of first study injection through Day 365.

Description of safety outcomes over 12 months post-vaccination including SAEs (serious adverse events), provincially reportable AEFIs (adverse events following immunization), MAAEs (medically attended adverse events), AESIs (adverse events of special interest).

From time of first study injection through Day 365.
Acceptability of vaccines as determined by participant-completed questionnaire after 2 doses
Lasso di tempo: Days 56, 140, and 365

Four 5 point likert scale type questions asking whether they would want to receive the vaccine again, recommend it to a friend, whether they were anxious about receiving it, and whether they would prefer a more painful injection if it conferred better protection.

Days 56, 140, and 365
Acceptability of vaccines as determined by participant-completed questionnaire after 3 doses
Lasso di tempo: Days 28, 180

Four 5 point likert scale type questions asking whether they would want to receive the vaccine again, recommend it to a friend, whether they were anxious about receiving it, and whether they would prefer a more painful injection if it conferred better protection.

Days 28, 180
Antibody to SARS-CoV-2 S and N, RBD after 3 doses
Lasso di tempo: Days 180 and 365

Assess durability of the immune responses in each study group over 12 months after the study vaccine.

Days 180 and 365
Pseudoneutralization assay, T cell testing, Antibody dependent cellular cytotoxicity after 3 doses
Lasso di tempo: Day 365

Further characterize the immune response to COVID-19 vaccine in schedules with homologous and heterologous third doses to day 365

Day 365
Incidence of grade 3 solicited local and systemic adverse events, SAEs, AEFIs, MAAEs, AESIs in the 7 days following vaccine receipt after 4 doses
Lasso di tempo: From time of first study injection through Day 365.

Description of safety outcomes over 12 months post-vaccination including SAEs (serious adverse events), provincially reportable AEFIs (adverse events following immunization), MAAEs (medically attended adverse events), AESIs (adverse events of special interest).

From time of first study injection through Day 365.
Acceptability of vaccines as determined by participant-completed questionnaire after 4 doses
Lasso di tempo: Days 28, 180

Four 5 point likert scale type questions asking whether they would want to receive the vaccine again(Yes, definitely; Yes, probably; I don't know; No, probably not; No, definitely not), recommend it to a friend(Yes, definitely; Yes, probably; I don't know; No, probably not; No, definitely not), whether they were anxious about receiving it(Not at all; A little; Moderately; Very; Extremely), and whether they would prefer a more painful injection if it conferred better protection(Vaccine A; Vaccine B; No preference; Unsure/don't know).

Days 28, 180
Antibody to SARS-CoV-2 S and N, RBD after 4 doses
Lasso di tempo: Days 180 and 365

Assess durability of the immune responses in each study group over 12 months after the study vaccine.

Days 180 and 365
Antibody dependent cellular cytotoxicity after 4 doses
Lasso di tempo: Day 365

Further characterize the immune response to COVID-19 vaccine in schedules with homologous and heterologous third doses to day 365

Day 365
Pseudoneutralization assay after 4 doses
Lasso di tempo: Day 365

Measuring the 50% Neutralization Titer to further characterize the immune response to COVID-19 vaccine in schedules with homologous and heterologous third doses to day 365

Day 365
T cell testing after 4 doses
Lasso di tempo: Day 365

Measuring the number of T cells to further characterize the immune response to COVID-19 vaccine in schedules with homologous and heterologous third doses to day 365

Day 365

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Exploratory assessment of interval between dose 1 and 2 on immune response after 3 or 4 doses
Lasso di tempo: From time of first study injection through Day 365.

Assess the role of intervals between first and second doses of the primary immunization schedule, and between 2nd and 3rd doses, on immune responses after the third dose over the study period.

From time of first study injection through Day 365.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

11 giugno 2021

Completamento primario (Effettivo)

25 luglio 2022

Completamento dello studio (Effettivo)

16 giugno 2023

Date di iscrizione allo studio

Primo inviato

18 maggio 2021

Primo inviato che soddisfa i criteri di controllo qualità

19 maggio 2021

Primo Inserito (Effettivo)

20 maggio 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

8 novembre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi